Metabolomics: Ethanol-induced metabolomic differences in the Gut-Liver-Pancreas Axis

Significance of the Topic

Excessive alcohol consumption is linked to a range of serious health conditions including alcoholic liver disease, pancreatitis, cardiovascular disorders, neuropsychiatric issues and cancer. While the pathological outcomes are well documented, the biochemical alterations within the interconnected gut-liver-pancreas axis remain poorly understood. By profiling metabolomic shifts across these key organs, researchers can uncover mechanistic insights and identify potential biomarkers for early detection and therapeutic intervention.

Objectives and Study Overview

This study aimed to characterize the metabolomic impact of chronic ethanol exposure on the gut, liver and pancreas in a mouse model. An untargeted high-resolution mass spectrometry approach was employed to detect and annotate significant metabolite changes across tissues following an eight-week Lieber-DeCarli ethanol diet.

Methodology and Used Instrumentation

• Animal model: C57BL/6 mice (8 controls, 8 ethanol-treated) fed ad libitum with a 5% ethanol liquid diet for 8 weeks under EU and national ethical approval.
• Sample preparation: Postmortem collection of gut, liver and pancreas tissues, homogenization, extraction and cleanup prior to analysis.
• Analytical platform: Shimadzu LCMS-9030 high-resolution LC-MS/MS configured for Data Independent Acquisition (DIA) and Data Dependent Acquisition (DDA).
• Mass range: m/z 100–1000 for MS scans and m/z 40–1000 for MS/MS scans.
• Data processing: Feature extraction using the Analyze algorithm in LabSolutions Insight, followed by statistical and pathway analysis using MetaboAnalyst.

Main Results and Discussion

PCA analysis revealed that tissue type drives the greatest variance, with ethanol treatment effects apparent within each organ cluster. Volcano plots identified numerous significantly altered metabolite features (fold change >2, p<0.05, FDR-corrected):

• Gut: 550 elevated and 385 reduced features. Increases in phospholipids and oleic acid ethyl ester; decreases in lyso-phospholipids, glycerophosphocholine and glycerophosphoethanolamine.
• Liver: 290 elevated and 233 reduced features. Prominent upregulation of fatty acid ethyl esters (log2 fold change >6) and N-acyl-taurines, suggesting adaptive lipid metabolism responses.
• Pancreas: 108 elevated and 428 reduced features. Predominantly downregulated monoacylglycerols (log2 decreases between 2 and 6), indicating disrupted energy storage pathways.

Shared metabolite alterations across all three tissues included decreases in LPC 22:5 sn-1 and LPE 22:5 sn-1. LPC 20:4 sn-2 exhibited differential regulation, increasing in the gut while decreasing in liver and pancreas.

Benefits and Practical Applications

• This untargeted metabolomics workflow enables rapid discovery of tissue-specific biomarkers of ethanol toxicity.
• The methodology can be adapted for toxicological screening and mechanistic studies in preclinical models.
• Findings highlight potential lipid mediators for future targeted analyses and therapeutic exploration.

Future Trends and Opportunities

• Integration with transcriptomics and proteomics to build a multi-omics atlas of alcohol-induced organ crosstalk.
• Development of targeted assays for validation of candidate biomarkers in clinical and forensic settings.
• Advances in spatial metabolomics to map location-specific changes within tissues.
• Application to human cohort studies to translate preclinical findings into patient diagnostics and treatment monitoring.

Conclusion

An untargeted HRMS LC-MS/MS approach effectively delineated ethanol-induced metabolomic perturbations across the gut-liver-pancreas axis in mice. Distinct lipid alterations were identified in each organ, with common signatures highlighting systemic biomarkers of alcohol toxicity. This work establishes a robust platform for future mechanistic research and potential clinical translation.